罗伯特·A·迈克尔
Robert A Michael
领导U.S.大型Pharmaceuticals企业运营
专业领域
Healthcare management, life sciences
核心贡献
领导U.S.大型Pharmaceuticals企业运营
Leading large-scale Pharmaceuticals operations in U.S.
最新观点
-
艾伯维董事长兼CEO迈克尔在2026年Q3业绩中表示,公司继续交出优异结果,反映多元组合的扎实执行;通过获得关键监管批准、产生差异化临床数据以及完成Apogee Therapeutics收购,进一步提升了长期增长潜力。基于强劲前景与显著动能,公司再次上调全年指引并提高季度股息(2027年起股息提高5.2%)。Q3营收174.04亿美元、同比增长10.3%,调整后每股收益3.82美元。
AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio. We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend.